CNMD (Conmed) Cyclically Adjusted Revenue per Share: $40.78 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CNMD Conmed Corp CNMD
80 GF Score
Price $51.38
GF Value $67.46
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Conmed Cyclically Adjusted Revenue per Share?

Conmed CNMD +0.25% 80 Cyclically Adjusted Revenue per Share is $40.78 as of Jun. 2026. GuruFocus rates CNMD with a GF Score™ of 80/100 and a GF Value™ of $67.46 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Conmed's adjusted revenue per share for the three months ended in Jun. 2026 was $11.405. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $40.78 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Conmed's average Cyclically Adjusted Revenue Growth Rate was 5.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 5.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Conmed was 26.30% per year. The lowest was 1.70% per year. And the median was 4.80% per year.

As of today (2026-08-21), Conmed's current stock price is $51.38. Conmed's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $40.78. Conmed's Cyclically Adjusted PS Ratio of today is 1.26.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Conmed was 4.95. The lowest was 0.81. And the median was 2.44.


Conmed  (NYSE:CNMD) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Conmed's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=51.38/40.78
=1.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Conmed was 4.95. The lowest was 0.81. And the median was 2.44.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Conmed Cyclically Adjusted Revenue per Share Related Terms


Conmed Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Conmed's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Conmed Cyclically Adjusted Revenue per Share Chart

Conmed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.16 34.13 35.67 37.36 39.27

Conmed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.57 39.10 39.27 40.14 40.78

CNMD vs ATEC, AORT, IRMD: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Conmed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Conmed Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Conmed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Conmed's Cyclically Adjusted PS Ratio falls into.


CNMD
80GF Score
Conmed Corp CNMD
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Conmed Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Conmed's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=11.405/333.9520*333.9520
=11.405

Current CPI (Jun. 2026) = 333.9520.

Conmed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 6.611 241.428 9.145
201612 7.284 241.432 10.075
201703 6.695 243.801 9.171
201706 7.006 244.955 9.551
201709 6.746 246.819 9.127
201712 7.861 246.524 10.649
201803 7.072 249.554 9.464
201806 7.378 251.989 9.778
201809 6.955 252.439 9.201
201812 8.376 251.233 11.134
201903 7.521 254.202 9.881
201906 8.122 256.143 10.589
201909 7.841 256.759 10.198
201912 8.853 256.974 11.505
202003 7.204 258.115 9.321
202006 5.528 257.797 7.161
202009 8.082 260.280 10.370
202012 7.835 260.474 10.045
202103 7.415 264.877 9.349
202106 7.860 271.696 9.661
202109 7.741 274.310 9.424
202112 8.352 278.802 10.004
202203 6.893 287.504 8.007
202206 9.309 296.311 10.492
202209 8.844 296.808 9.951
202212 8.229 296.797 9.259
202303 9.469 301.836 10.477
202306 9.991 305.109 10.935
202309 9.611 307.789 10.428
202312 10.381 306.746 11.302
202403 9.986 312.332 10.677
202406 10.676 314.175 11.348
202409 10.179 315.301 10.781
202412 11.104 315.605 11.750
202503 10.313 319.799 10.769
202506 11.024 322.561 11.413
202509 10.883 324.800 11.190
202512 11.976 324.054 12.342
202603 10.354 330.213 10.471
202606 11.405 333.952 11.405

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $40.78 mean?
Conmed (CNMD) has a Cyclically Adjusted Revenue per Share of $40.78 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Conmed and its competitors.
Is Conmed's Cyclically Adjusted Revenue per Share too high?
Conmed's current Cyclically Adjusted Revenue per Share is $40.78. Overall, Conmed has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Conmed's Cyclically Adjusted Revenue per Share compare to ATEC and AORT?
Conmed's Cyclically Adjusted Revenue per Share of $40.78 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Conmed and its competitors. Conmed's current Cyclically Adjusted Revenue per Share is $40.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Conmed stock overvalued right now?
Based on GuruFocus' analysis, Conmed (CNMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $67.46, compared to a current price of $51.38 — trading 23.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $40.78. Conmed's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Conmed (CNMD), the current Cyclically Adjusted Revenue per Share is $40.78 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Conmed (CNMD) Overvalued in 2026?

Based on GuruFocus' analysis, Conmed stock appears to be undervalued. The current stock price of $51.38 is trading 23.8% below its estimated GF Value™ of $67.46. GuruFocus considers Conmed to be Modestly Undervalued.

Key valuation signals for CNMD:

  • Cyclically Adjusted Revenue per Share: $40.78
  • GF Value™: $67.46 vs. price of $51.38 (23.8% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the CNMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Conmed Business Description

Other Exchanges EC8:Germany
Address 11311 Concept Boulevard, Largo, FL, USA, 33773
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
80GF Score

Get the complete analysis for CNMD

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$51.38
Price
$67.46
GF Value